KSF notice sets Sept. 28 deadline in Capricor securities class action
Kahn Swick & Foti posted a notice on a Capricor Therapeutics securities class action and said investors who suffered losses during the alleged class period have until Sept. 28, 2026, to request lead-plaintiff status.
Kahn Swick & Foti said investors in Capricor Therapeutics who bought shares during a disputed period have until Sept. 28, 2026, to seek lead-plaintiff appointment in a federal case in California.
Kahn Swick & Foti, LLC posted a notice on Aug. 14 about a securities class action involving Capricor Therapeutics, Inc., a Nasdaq-listed biotech company. The case is pending in the U.S. District Court for the Southern District of California under Nkamga v. Capricor Therapeutics, Inc., et al., No. 3:26-cv-04385.
The notice said investors who purchased or otherwise acquired Capricor securities between Dec. 17, 2025, and July 26, 2026, may seek appointment as lead plaintiff by Sept. 28, 2026. It also said investors do not need to serve as lead plaintiff to share in any recovery.
According to the notice, the suit alleges that Capricor and certain executives failed to disclose material information during the class period, in violation of federal securities laws. The claims have not been adjudicated.
The notice said the dispute centers on Capricor’s Biologics License Application for Deramiocel. It said the Food and Drug Administration released briefing documents on July 27, 2026, before a July 29 advisory committee meeting.
The notice said the FDA stated that Capricor changed the pre-specified statistical analysis plan, that the final version was not submitted for FDA review before the BLA filing and was not agreed upon, and that analyses based on later versions of the plan were post-hoc and exploratory. It also said the FDA viewed the benefit-risk profile for Deramiocel as unfavorable because of a lack of evidence supporting effectiveness.
The notice said Capricor stock fell $12.70, or 64%, to close at $7.00 per share on July 27, 2026, on unusually heavy trading volume. Those price moves were described in the notice and were linked there to the FDA briefing documents.
The notice said interested investors can contact Kahn Swick & Foti for more information.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()